imiquimod has been researched along with Adverse Drug Event in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cao, J; Che, D; Gao, J; Geng, S; Han, H; Hao, Y; He, L; Kong, S; Liu, R; Peng, B; Shi, J; Wang, J; Zhang, Y; Zheng, Y | 1 |
| Banney, L; Buzacott, K; Malla, U; Tedman, A; Vasanthakumar, L | 1 |
| Dutton, P; Fiander, A; Griffiths, G; Hibbitts, S; Hurt, CN; Jones, S; Madden, T; Man, S; Naik, R; Nordin, AJ; Powell, N; Tristram, A | 1 |
| Battiste, JL; Harrison, LI; Nelson, RJ; Stoesz, JD; Zarraga, IE | 1 |
| Célestin Schartz, NE; Chevret, S; Kerob, D; Lebbé, C; Morel, P; Paz, C; Verola, O | 1 |
2 trial(s) available for imiquimod and Adverse Drug Event
| Article | Year |
|---|---|
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cidofovir; Cytosine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imiquimod; Middle Aged; Neoplasm Grading; Organophosphonates; Vulvar Neoplasms | 2014 |
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Drug-Related Side Effects and Adverse Reactions; Female; HIV Seronegativity; Humans; Imiquimod; Male; Middle Aged; Patient Compliance; Prospective Studies; Sarcoma, Kaposi; Skin Neoplasms | 2008 |
5 other study(ies) available for imiquimod and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2.
Topics: Animals; Calcium Signaling; Cell Degranulation; Dermatitis; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; HEK293 Cells; Humans; Imiquimod; Male; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, G-Protein-Coupled | 2020 |
Stevens-Johnson syndrome due to topical imiquimod 5%.
Topics: Administration, Topical; Aged; Blister; Conjunctivitis; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imiquimod; Oral Ulcer; Stevens-Johnson Syndrome | 2020 |
A pharmaceutical comparison of different commercially available imiquimod 5% cream products.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Labeling; Drug Stability; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Humans; Imiquimod; Ointments; Probability; Sensitivity and Specificity; Structure-Activity Relationship; Therapeutic Equivalency | 2009 |